Frontotemporal dementia. How to deal with its diagnostic complexity? DOI Creative Commons
Annibale Antonioni,

Emanuela Maria Raho,

Enrico Granieri

et al.

Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 6, 2025

Frontotemporal dementia (FTD) encompasses a group of heterogeneous neurodegenerative disorders. Aside from genetic cases, its diagnosis is challenging, particularly in the early stages when symptoms are ambiguous, and structural neuroimaging does not reveal characteristic patterns. The authors performed comprehensive literature search through MEDLINE, Scopus, Web Science databases to gather evidence aid diagnostic process for suspected FTD patients, phases, even sporadic ranging established promising tools. Blood-based biomarkers might help identify very neuropathological guide further evaluations. Subsequently, neurophysiological measures reflecting functional changes cortical excitatory/inhibitory circuits, along with assessing brain network, connectivity, metabolism, perfusion alterations, could detect specific associated decades before symptom onset. As advances, cognitive-behavioral profiles atrophy patterns emerge, distinguishing subtypes. Emerging disease-modifying therapies require patient enrollment. Therefore, paradigm shift needed - relying on typical cognitive advanced cases widely applicable biomarkers, primarily fluid and, subsequently, where appropriate. Additionally, exploring subjective complaints behavioral detected by home-based technologies be crucial diagnosis.

Language: Английский

Aging and aging-related diseases: from molecular mechanisms to interventions and treatments DOI Creative Commons
Jun Guo, Xiuqing Huang, Lin Dou

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Dec. 16, 2022

Aging is a gradual and irreversible pathophysiological process. It presents with declines in tissue cell functions significant increases the risks of various aging-related diseases, including neurodegenerative cardiovascular metabolic musculoskeletal immune system diseases. Although development modern medicine has promoted human health greatly extended life expectancy, aging society, variety chronic diseases have gradually become most important causes disability death elderly individuals. Current research on focuses elucidating how endogenous exogenous stresses (such as genomic instability, telomere dysfunction, epigenetic alterations, loss proteostasis, compromise autophagy, mitochondrial cellular senescence, stem exhaustion, altered intercellular communication, deregulated nutrient sensing) participate regulation aging. Furthermore, thorough pathogenesis to identify interventions that promote longevity caloric restriction, microbiota transplantation, nutritional intervention) clinical treatment methods for (depletion senescent cells, therapy, antioxidative anti-inflammatory treatments, hormone replacement therapy) could decrease incidence turn healthy longevity.

Language: Английский

Citations

690

Biomarkers of aging DOI Open Access

Hainan Bao,

Jiani Cao, Mengting Chen

et al.

Science China Life Sciences, Journal Year: 2023, Volume and Issue: 66(5), P. 893 - 1066

Published: April 11, 2023

Language: Английский

Citations

197

Magnetic iron oxide nanoparticles for brain imaging and drug delivery DOI Creative Commons
Ruirui Qiao, Changkui Fu, Helen Forgham

et al.

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 197, P. 114822 - 114822

Published: April 21, 2023

Central nervous system (CNS) disorders affect as many 1.5 billion people globally. The limited delivery of most imaging and therapeutic agents into the brain is a major challenge for treatment CNS disorders. With advent nanotechnologies, controlled drugs with nanoparticles holds great promise in overcoming blood-brain barrier (BBB) improving efficacy. In recent years, magnetic iron oxide (MIONPs) have stood out promising theranostic nanoplatform drug they possess unique physical properties biodegradable characteristics. this review, we summarize advances MIONP-based platforms diseases. We firstly introduce methods synthesis surface functionalization MIONPs emphasis on inclusion biocompatible polymers that allow addition tailored physicochemical properties. then discuss vivo applications using MIONPs. Finally, present perspective remaining challenges possible future directions systems.

Language: Английский

Citations

110

Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management DOI Creative Commons
Baljinder Singh, Candace M. Day, Sadikalmahdi Abdella

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 367, P. 402 - 424

Published: Feb. 2, 2024

Alzheimer's disease (AD), is a neurodegenerative disorder that escalates with time, exerting significant impact on physical and mental health leading to death. The prevalence of AD progressively rising along its associated economic burden necessitates effective therapeutic approaches in the near future. This review paper aims offer an insightful overview pathogenesis, current FDA-approved drugs, drugs different clinical phases. It also explores innovative formulations drug delivery strategies, focusing nanocarriers long-acting medications (LAMs) enhance treatment efficacy patient adherence. emphasizes preclinical evidence related their potential improve bioavailability, pharmacokinetics, pharmacodynamics parameters, while highlighting ability minimize systemic side effects. By providing comprehensive analysis, this furnishes valuable insights into pathophysiological mechanisms for future development. inform development strategies formulation delivering existing molecules disease, ultimately striving compliance.

Language: Английский

Citations

50

Kaempferol: Paving the path for advanced treatments in aging-related diseases DOI Creative Commons
Md Sadique Hussain, Abdulmalik Saleh Alfawaz Altamimi, Muhammad Afzal

et al.

Experimental Gerontology, Journal Year: 2024, Volume and Issue: 188, P. 112389 - 112389

Published: March 8, 2024

Aging-related diseases (ARDs) are a major global health concern, and the development of effective therapies is urgently needed. Kaempferol, flavonoid found in several plants, has emerged as promising candidate for ameliorating ARDs. This comprehensive review examines Kaempferol's chemical properties, safety profile, pharmacokinetics, highlights its potential therapeutic utility against underpinned by distinctive structure, which confers antioxidative anti-inflammatory properties. Kaempferol counteracts reactive oxygen species (ROS) modulates crucial cellular pathways, thereby combating oxidative stress inflammation, hallmarks low toxicity wide margins, demonstrated preclinical clinical studies, further substantiate potential. Compelling evidence supports substantial addressing ARDs through mechanisms, notably anti-inflammatory, antioxidant, anti-apoptotic actions. exhibits versatile neuroprotective effect modulating various proinflammatory signaling including NF-kB, p38MAPK, AKT, β-catenin cascade. Additionally, it hinders formation aggregation beta-amyloid protein regulates brain-derived neurotrophic factors. In terms anticancer potential, kaempferol acts diverse inducing apoptosis, arresting cell cycle at G2/M phase, suppressing epithelial-mesenchymal transition (EMT)-related markers, affecting phosphoinositide 3-kinase/protein kinase B pathways. Subsequent studies should focus on refining dosage regimens, exploring innovative delivery systems, conducting trials to translate these findings into applications.

Language: Английский

Citations

48

Targeting synapse function and loss for treatment of neurodegenerative diseases DOI
Borislav Dejanovic, Morgan Sheng, Jesse E. Hanson

et al.

Nature Reviews Drug Discovery, Journal Year: 2023, Volume and Issue: 23(1), P. 23 - 42

Published: Nov. 27, 2023

Language: Английский

Citations

41

The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders DOI Creative Commons
Ying‐Chieh Wu,

Tizibt Ashine Bogale,

Jari Koıstınaho

et al.

Acta Neuropathologica, Journal Year: 2024, Volume and Issue: 147(1)

Published: Feb. 12, 2024

Abstract Central nervous system (CNS) accumulation of fibrillary deposits made Amyloid β (A ), hyperphosphorylated Tau or α -synuclein ( -syn), present either alone in the form mixed pathology, characterizes most common neurodegenerative diseases (NDDs) as well aging brain. Compelling evidence supports that acute neurological disorders, such traumatic brain injury (TBI) and stroke, are also accompanied by increased deposition toxic A , -syn species. While contribution these pathological proteins to neurodegeneration has been experimentally ascertained, cellular molecular mechanisms driving -syn-related damage remain be fully clarified. In last few years, studies have shown may contribute inducing and/or promoting blood–brain barrier (BBB) disruption. These can affect BBB integrity directly affecting key components pericytes endothelial cells (ECs) indirectly, macrophages activation dysfunction. Here, we summarize critically discuss findings showing how NDDs, TBI stroke. We highlight need for a deeper characterization role dysfunction macrophages, ECs improve diagnosis treatment chronic disorders.

Language: Английский

Citations

28

Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes DOI Creative Commons
Hannah Scheiblich,

Frederik Eikens,

Lena Wischhof

et al.

Neuron, Journal Year: 2024, Volume and Issue: 112(18), P. 3106 - 3125.e8

Published: July 25, 2024

Microglia are crucial for maintaining brain health and neuron function. Here, we report that microglia establish connections with neurons using tunneling nanotubes (TNTs) in both physiological pathological conditions. These TNTs facilitate the rapid exchange of organelles, vesicles, proteins. In neurodegenerative diseases like Parkinson's Alzheimer's disease, toxic aggregates alpha-synuclein (α-syn) tau accumulate within neurons. Our research demonstrates use to extract from these aggregates, restoring neuronal health. Additionally, share their healthy mitochondria burdened neurons, reducing oxidative stress normalizing gene expression. Disrupting mitochondrial function antimycin A before TNT formation eliminates this neuroprotection. Moreover, co-culturing promoting rescues suppressed activity caused by α-syn or aggregates. Notably, TNT-mediated aggregate transfer is compromised carrying Lrrk22(Gly2019Ser) Trem2(T66M) (R47H) mutations, suggesting a role pathology variants diseases.

Language: Английский

Citations

27

Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia DOI Creative Commons
Bram van der Gaag,

Natasja A. C. Deshayes,

John J. P. Brevé

et al.

Acta Neuropathologica, Journal Year: 2024, Volume and Issue: 147(1)

Published: Jan. 10, 2024

Abstract Alpha-synuclein (aSyn) pathology is present in approximately 50% of Alzheimer’s disease (AD) cases at autopsy and might impact the age-of-onset progression AD. Here, we aimed to determine whether tau aSyn profiles differ between AD with Lewy bodies (AD-LB), pure Parkinson’s dementia (PDD) using epitope-, post-translational modification- (PTM) isoform-specific antibody panels spanning from N- C-terminus. We included middle temporal gyrus (MTG) amygdala (AMY) clinically diagnosed pathologically confirmed performed dot blotting, western blotting immunohistochemistry combined quantitative morphological analyses. All investigated phospho-tau (pTau) species, except pT181, were upregulated AD-LB compared PDD control cases, but no significant differences observed subjects. In addition, antibodies targeting proline-rich regions C-terminus showed preferential binding brain homogenates. Antibodies C-terminal epitopes pS129 stronger cases. Two pTau species (pS198 pS396) specifically detected soluble protein fractions subjects, indicative early involvement these PTMs multimerization process tau. Other phospho-variants for both (pT212/S214, pT231 pS422) (pS129) only insoluble fraction AD-LB/AD AD-LB/PDD respectively. load was higher AMY suggesting aggravated under presence pathology, while similar Co-localization could be within astrocytes MTG. These findings highlight a unique pathological signature

Language: Английский

Citations

18

Type 2 Diabetes Mellitus Exacerbates Pathological Processes of Parkinson's Disease: Insights from Signaling Pathways Mediated by Insulin Receptors DOI Creative Commons
Shufen Liu, Tingting Liu, Jingwen Li

et al.

Neuroscience Bulletin, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

Language: Английский

Citations

2